Bristol myers Squibb Company (BMY) |
|
Price: $51.5900
$-0.75
-1.433%
|
Day's High:
| $52.7
| Week Perf:
| -5.17 %
|
Day's Low: |
$ 51.62 |
30 Day Perf: |
4.35 % |
Volume (M): |
1,007 |
52 Wk High: |
$ 71.07 |
Volume (M$): |
$ 52,068 |
52 Wk Avg: |
$58.53 |
Open: |
$52.32 |
52 Wk Low: |
$47.58 |
|
|
Market Capitalization (Millions $) |
107,256 |
Shares
Outstanding (Millions) |
2,079 |
Employees |
32,200 |
Revenues (TTM) (Millions $) |
45,006 |
Net Income (TTM) (Millions $) |
8,040 |
Cash Flow (TTM) (Millions $) |
2,194 |
Capital Exp. (TTM) (Millions $) |
1,209 |
Bristol Myers Squibb Company
Bristol-Myers Squibb Company was incorporated under the laws of the State of Delaware
in August 1933 under the name Bristol-Myers Company, as successor to a New York
business started in 1887. In 1989, Bristol-Myers Company changed its name to Bristol-Myers
Squibb Company as a result of a merger. The Company, through its divisions and
subsidiaries, is engaged in the discovery, development, licensing, manufacturing,
marketing, distribution and sale of pharmaceuticals and other healthcare related
products.
The Company has four reportable segments'Pharmaceuticals, Oncology Therapeutics
Network (OTN), Nutritionals and Other Healthcare. The Pharmaceuticals segment
is made up of the global pharmaceutical and international (excluding Japan)
consumer medicines business. The OTN segment provides oncology products, supportive
care products and related supplies to office-based oncologists in the United
States. The Nutritionals segment consists of Mead Johnson Nutritionals (Mead
Johnson), primarily an infant formula business. The Other Healthcare segment
consists of ConvaTec, Medical Imaging and Consumer Medicines (North America
and Japan) businesses.
In the Company's Pharmaceuticals segment and in its ConvaTec and Medical Imaging
businesses, the Company promotes its products in medical journals and directly
to health care providers such as doctors, nurse practitioners, physician assistants,
pharmacists, hospitals, Pharmacy Benefit Managers (PBMs), Managed Care Organizations
(MCOs) and government agencies. The Company also markets directly to consumers
in the United States through direct-to-consumer print, radio and television
advertising.
The Company's operations include several pharmaceutical sales organizations.
Each sales organization markets a distinct group of products and is typically
based on particular therapeutic areas or physician groups. These sales organizations
often focus on selling new products when they are introduced, and marketing
to physicians is increasingly targeted at specialists and high value primary
care physicians.
The Company's prescription pharmaceutical products are sold principally to
wholesalers, but the Company also sells directly to retailers, hospitals, clinics,
government agencies and pharmacies.'Pharmaceutical wholesalers in the United
States are;'McKesson Corporation (McKesson), Cardinal and AmerisourceBergen
Corporation.
Competition
The markets in which Bristol-Myers Squibb competes are generally broad-based
and highly competitive. The principal means of competition vary among product
categories and business groups.
The Company's Pharmaceuticals segment competes with other worldwide research-based
drug companies, many smaller research companies with more limited therapeutic
focus and generic drug manufacturers. Important competitive factors include
product efficacy, safety and ease of use, price and demonstrated cost-effectiveness,
marketing effectiveness, product labeling, service and research and development
of new products and processes. Sales of the Company's products can be impacted
by new studies that indicate a competitor's product has greater efficacy for
treating a disease or particular form of disease than one of the Company's products.
Company Address: Route 206 & Province Line Road Princeton 8543 NJ
Company Phone Number: 252-4621 Stock Exchange / Ticker: NYSE BMY
|
|
Customers Net Income fell by |
BMY's Customers Net Profit Margin fell to |
-11.5 % |
2.66 %
|
|
|
|
|
|
Stock Performances by Major Competitors |
|
|
Business Update
Published Fri, Feb 23 2024 11:59 AM UTC
Bristol Myers Squibb, a leading global biopharmaceutical company, has announced that its tender offer to acquire all outstanding shares of RayzeBio, Inc. has expired. The company's decision comes as it faces challenges in its supplier revenues and an increase in the cost of sales. This article aims to ly analyze the facts surrounding these developments.1. Bristol Myers Squib...
|
Bristol Myers Squibb Company
Bristol Myers Squibb (BMY), a leading player in the Major Pharmaceutical Preparations sector, recently announced the completion of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, or the HSR Act, in relation to its tender offer to acquire all outstanding shares of RayzeBio, Inc. (RYZB) for a total cash price of $4.1 billion. This milestone marks an important step in the merger process between the two companies and underscores their shared vision for the future. BMY has established itself as a major player in the industry with over 2,073,118,279.5699 million shares outstanding. Currently, the company's stock is being traded at $49.7525, reflecting its stability and potential for growth. Despite some challenges in their recent financial report, BMY remains a promising investment option.
|
Merger and Acquisition
Published Mon, Feb 12 2024 11:59 AM UTC
PRINCETON, N.J. & SAN DIEGO - Bristol Myers Squibb (NYSE: BMY) and RayzeBio, Inc. (Nasdaq: RYZB) jointly declared today the culmination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, also known as the HSR Act, in relation to Bristol Myers Squibb's previously disclosed tender offer to procure all of the exceptional shares of RayzeBio com...
|
Merger and Acquisition
Published Tue, Jan 23 2024 1:30 PM UTC
Bristol Myers Squibb Completes Acquisition of Mirati Therapeutics, Strengthening and Diversifying Oncology Portfolio Princeton, New Jersey - Bristol Myers Squibb (NYSE: BMY) has recently announced the successful completion of its acquisition of Mirati Therapeutics, Inc. (Mirati), marking a significant milestone in the company's efforts to expand and enhance its oncology ...
|
Product Service News
Published Mon, Dec 11 2023 9:15 PM UTC
SystImmune and Bristol Myers Squibb Form Global Partnership for Innovative Cancer Treatment In a groundbreaking collaboration, clinical-stage biopharmaceutical company SystImmune and Bristol Myers Squibb (BMY) have joined forces to develop and commercialize BL-B01D1, a potentially revolutionary EGFRxHER3 bispecific antibody-drug conjugate (ADC). This strategic partnersh...
|
Per Share |
Current |
Earnings (TTM) |
3.86 $ |
Revenues (TTM) |
21.65 $
|
Cash Flow (TTM) |
1.06 $ |
Cash |
5.91 $
|
Book Value |
14.18 $
|
Dividend (TTM) |
2.27 $ |
|
Per Share |
|
Earnings (TTM) |
3.86 $
|
Revenues (TTM) |
21.65 $ |
Cash Flow (TTM) |
1.06 $ |
Cash |
5.91 $
|
Book Value |
14.18 $ |
Dividend (TTM) |
2.27 $ |
|
|
|
Eliquis |
|
Segment |
|
|
of total Revenue |
SPRYCEL |
|
Segment |
|
|
of total Revenue |
ABILIFY |
|
Segment |
|
|
of total Revenue |
Erbitux |
|
Segment |
|
|
of total Revenue |
SUSTIVA |
|
Segment |
|
|
of total Revenue |
BARACLUDE |
|
Segment |
|
|
of total Revenue |
ORENCIA |
|
Segment |
|
|
of total Revenue |
Other |
|
Segment |
|
|
of total Revenue |
Total Pharmaceuticals |
|
Segment |
|
|
of total Revenue |
|
|
Company Estimates |
|
|
• Revenue Outlook
Bristol Myers Squibb announced annual revenue outlook on
• Earnings Outlook
Bristol myers Squibb Company issued annual earnings guidance on
|
|
|
|
|
|